## **Report From Agency**

## STATE OF WISCONSIN CONTROLLED SUBSTANCES BOARD

\_\_\_\_\_

IN THE MATTER OF RULEMAKING:

PROCEEDINGS BEFORE THE : REPORT TO THE LEGISLATURE

CONTROLLED SUBSTANCES BOARD: CR 20-058

I. THE PROPOSED RULE:

The proposed rule, including the analysis and text, is attached.

- II. REFERENCE TO APPLICABLE FORMS: n/a
- III. FISCAL ESTIMATE AND EIA:

The Fiscal Estimate and EIA is attached.

IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:

On January 31, 2020, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register placing lasmiditan into Schedule V of the federal Controlled Substances Act.

The Controlled Substances Board did not receive an objection to treating lasmiditan as a schedule V controlled substance under ch. 961, Stats. based upon the federal scheduling. The Controlled Substances Board took affirmative action on March 13, 2020 to similarly treat lasmiditan under chapter 961 effective March 23, 2020 to allow for publication in the Administrative Register. The Affirmative Action Order will expire upon promulgation of a final rule.

This rule creates s. 961.22 (8), Stats. which adds lasmiditan to schedule V.

V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:

Per s. 961.11(4), Stats., if no objection is made, the board shall promulgate a final rule for which notice of proposed rulemaking is omitted. Therefore, the Board did not hold a public hearing.

VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:

Legislative Council staff did not make any recommendations.

## VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A